Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
50
Trial Sponsor
Clinical Trial Start Date
May 31, 2022
0Primary Completion Date
August 11, 2023
0Study Completion Date
August 11, 2023
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Combination Product0
Drug0
Intervention Name
Fludarabine0
FT5360
Cyclophosphamide0
Cetuximab0
Avelumab0
Atezolizumab0
Amivantamab0
Nivolumab0
...
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors0
Last Updated
September 21, 2023
0Allocation Type
Non-Randomized0
Intervention Model
Sequential Assignment0
Masking Type
None (Open Label)0
Study summary
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
